Actuate Therapeutics, Inc. (ACTU) Stock Price & Analysis
Actuate Therapeutics, Inc. (ACTU) fell 2.99% to USD 1.95 as of June 10, 2026 at 16:18 UTC, according to Nexqual real-time market data.
ACTU last closed at USD 2.01; the session ranged USD 1.9–2.02 on volume of 74,402 shares. Market capitalization is $46.66M, with a 52-week range of USD 1.58–9.25 (NGM). Source: Nexqual, June 10, 2026 at 16:18 UTC.
Key Statistics (as of June 10, 2026 at 16:18 UTC)
| Price | USD 1.95 |
|---|---|
| Change | ▼ 2.99% (down) |
| Previous Close | USD 2.01 |
| Open | USD 1.92 |
| Day Range | USD 1.9 – 2.02 |
| 52-Week Range | USD 1.58 – 9.25 |
| Volume | 74,402 shares |
| Market Cap | $46.66M |
| Exchange | NGM |
Technical Analysis (ACTU)
Nexqual's technical model rates ACTU "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of June 10, 2026 at 16:18 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.81 (neutral) |
| vs SMA50 | Below (USD 2.43) |
| MACD | -0.21 (negative) |
Analyst Ratings (ACTU)
Wall Street analysts rate ACTU "Strong Buy" based on 4 analysts, with a mean price target of USD 9.98 (range USD 5–14.91), per Nexqual as of June 10, 2026 at 16:18 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 9.98 |
| High Target | USD 14.91 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ACTU)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.24 vs est -0.21 ▼ miss |
| 2025-12-31 | USD -0.18 vs est -0.25 ▲ beat |
| 2025-09-30 | USD -0.25 vs est -0.28 ▲ beat |
| 2025-06-30 | USD -0.3 vs est -0.32 ▲ beat |
Source: Nexqual, June 10, 2026 at 16:18 UTC.
Financials & Fundamentals (ACTU)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.8 |
| Total Cash | $8.13M |
| Total Debt | $0 |
| Free Cash Flow | $-11.84M |
Source: Nexqual, June 10, 2026 at 16:18 UTC.
Financial Health Score (ACTU)
Nexqual rates Actuate Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 16:18 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $8M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Mixed — No data |
Ownership (ACTU)
| Insider Ownership | +15.36% |
|---|---|
| Institutional Ownership | +58.16% |
| Shares Outstanding | 23.93M |
| Float | 8.57M |
| Short % of Float | +8.79% |
Source: Nexqual, June 10, 2026 at 16:18 UTC.
Leadership (ACTU)
Actuate Therapeutics, Inc. is led by Daniel M. Schmitt (age 63), CEO, President & Director, per Nexqual as of June 10, 2026 at 16:18 UTC.
| CEO, President & Director | Daniel M. Schmitt (age 63) |
|---|---|
| Co-Founder & COO | Andrew P. Mazar (age 63) |
| Chief Financial Officer | Paul J. Lytle (age 57) |
Major Backers & Investors (ACTU)
Notable institutional backers of Actuate Therapeutics, Inc. include Bios Capital Management, LP , Voss Capital, LP, Fidelity, according to Nexqual as of June 10, 2026 at 16:18 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bios Capital Management, LP | 42% |
| Voss Capital, LP | 7.21% |
| Fidelity | 0.63% |
| Connective Capital Management LLC | 0.47% |
| Palogic Value Management, LP | 0.42% |
| Texas Capital Bank Wealth Management Services, Inc. | 0.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.5% |
| BlackRock | 2.97% |
| Geode Capital | 0.95% |
| Northern Trust | 0.41% |
Source: Nexqual, June 10, 2026 at 16:18 UTC.
From Actuate Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.
- The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
- It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACTL | ARTEC GLOBAL MEDIA INC | USD 0 | ▲ 0% |
| ACCL | Acco Group Holdings Limited | USD 1.54 | ▼ 0.45% |
| CHRD | Chord Energy Corporation | USD 139.33 | ▲ 0.77% |
| SY | So-Young International Inc. - A | USD 1.91 | ▲ 4.37% |
| CPWR | Ocean Thermal Energy Corp. | USD 0.01 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 16:18 UTC. This page is informational and not investment advice.